KN026 (anti-HER2 bispecific antibody) in patients with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancer

Jianming Xu(Chinese PLA General Hospital), Qian Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Rongrui Liu(Chinese PLA General Hospital), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaojun Xiang(Ministry of Agriculture and Rural Affairs), Xionghui Li, Xiaoyan Lin(Fujian Medical University), Feng Ye(Shanghai Sunshine Rehabilitation Center), Suxia Luo(Zhengzhou University), Jianhong Wang(Nantong Tumor Hospital), Huiting Xu(Hubei Cancer Hospital), Jun Wu(The First People's Hospital of Changzhou), Baohong Guo, Yanqiao Zhang(Harbin Medical University), Shegan Gao(First Affiliated Hospital of Henan University of Science and Technology), Yangzhi Su, Nong Xu(First Affiliated Hospital Zhejiang University), Rusen Zhao(Central Hospital of Zibo)
European Journal of Cancer
October 19, 2022
10.1016/j.ejca.2022.10.004
Cited by 54

Related Papers

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
|Molecular Cancer|2019|1.2k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet|2023|701